DEAN JACK H 4

What Happened

• Jack H. Dean, a director of Acurx Pharmaceuticals, was granted a derivative award on 2026-04-20 covering 2,150 shares (reported as acquisition A). The filing lists a price of $0.00 for the award; a footnote identifies this as a stock option grant under the company’s Director Compensation Policy. The options vest on April 20, 2027. This is a compensation grant (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-04-20; Form 4 filed: 2026-04-22 (filed within the typical 2-business-day window).
• Transaction type/code: Award/Grant (A); 2,150 derivative shares; price reported $0.00.
• Vesting: Shares subject to the options vest on April 20, 2027 (per footnote).
• Shares owned after transaction: Not specified in the Form 4.
• No 10b5-1 plan, sale, tax withholding, or late-filing indication noted in the filing.

Context

• This is an option award as part of director compensation and does not reflect an immediate purchase or sale of stock. The award will only become exercisable/vest after the stated vesting date; it does not by itself indicate insider sentiment about the stock.